Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZG0418 in ALK-positive NSCLC After Crizotinib Failure
CTR20192178Phase 2Terminated
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Nov 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of alkotinib in ALK-positive non-small cell lung cancer, sponsored by Suzhou Zelgen Biopharmaceuticals. Started Nov 2019; status: terminated.
02
Drugs
alkotinib
03
Conditions
ALK-positive non-small cell lung cancer
Beyond the preview
Go deeper on CTR20192178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192178.